Compare Mondaycom Ltd (MNDY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Tango Therapeutics Inc. — how do they compare? Mondaycom Ltd trades at $87.2 (market cap $3.57B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Mondaycom Ltd and Tango Therapeutics Inc. are close in size by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Tango Therapeutics Inc. for 0 Days on average.
| MNDY | TNGX | |
|---|---|---|
Market Cap | $3.57B | $3.75B |
Volume | 1,023,013 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $205.24 | $32.90 |
52-Week Low | $58.81 | $7.50 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $2.74B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $84.69, showing minimal daily movement (-0.08%) with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust revenue growth from $1.23B to $1.4B. Recent news highlights AI integration at Elevate '26 conference and inclusion in multiple growth stock lists, while technical indicators show mixed signals with RSI at neutral levels and key support at $83.
The stock presents a compelling growth story with 61.5% analyst buy ratings and a $108.64 consensus target offering 28% upside. However, elevated valuation multiples (P/E 35.83, EV/EBITDA 50.12) and competitive pressures from Meta's enterprise software push pose risks. Net cash flow turned negative in 2026 (-$737M) despite strong operating performance, requiring monitoring of capital allocation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
